Cited by 248Attention Deficit Hyperactivity DisorderNeurotransmitter Receptor Influence on BehaviorSchizophrenia research and treatment

Attention-deficit-hyperactivity disorder and reward deficiency syndrome

Open access
Oscar Berman, Marlene, Blum, Kenneth, Chen, Thomas JH, Braverman, Eric, Waite, Roger, Downs, William, Arcuri, Vanessa, Notaro, Ali +2 more·2008·Neuropsychiatric Disease and Treatment

Abstract

Molecular genetic studies have identified several genes that may mediate susceptibility to attention deficit hyperactivity disorder (ADHD). A consensus of the literature suggests that when there is a dysfunction in the "brain reward cascade," especially in the dopamine system, causing a low or hypo-dopaminergic trait, the brain may require dopamine for individuals to avoid unpleasant feelings. This high-risk genetic trait leads to multiple drug-seeking behaviors, because the drugs activate release of dopamine, which can diminish abnormal cravings. Moreover, this genetic trait is due in part to a form of a gene (DRD(2) A1 allele) that prevents the expression of the normal laying down of dopamine receptors in brain reward sites. This gene, and others involved in neurophysiological processing of specific neurotransmitters, have been associated with deficient functions and predispose individuals to have a high risk for addictive, impulsive, and compulsive behavioral propensities. It has been proposed that genetic variants of dopaminergic genes and other "reward genes" are important common determinants of reward deficiency syndrome (RDS), which we hypothesize includes ADHD as a behavioral subtype. We further hypothesize that early diagnosis through genetic polymorphic identification in combination with DNA-based customized nutraceutical administration to young children may attenuate behavioral symptoms associated with ADHD. Moreover, it is concluded that dopamine and serotonin releasers might be useful therapeutic adjuncts for the treatment of other RDS behavioral subtypes, including addictions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ndt.s2627

Cites

108 of 108 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

3 of the 111 references couldn’t be matched to a known paper.

Research works printed but not linked: 4

  1. Blum K Meshkin B Downs BW 2006b DNA based customized nutraceutical “gene therapy” utilizing a genoscore: a hypothesized paradigm shift of a novel approach to the diagnosis, stratification, prognosis and treatment of inflammatory processes in the human Med Hypotheses 66 1008 18 16403602
  2. Blum K Sheridan PJ Wood RC 1996b The D2 dopamine receptor gene as a determinant of reward deficiency syndrome J R Soc Med 89 396 400 8774539 PMC1295855
  3. Conners CK 2006 CRS-R (Conners’ Rating Scales-Revised) Minneapolis, MN Pearson Assessment Group
  4. Noble EP Gottschalk LA Fallon JH 1997 D2 dopamine receptor polymorphism and brain regional glucose metabolism Am J Med Genet 74 162 6 9129716

Cited by

Sorted by citations

Authors
Oscar Berman, M., Blum, K., Chen, T. J., Braverman, E., Waite, R., Downs, W., Arcuri, V., Notaro, A., Palomo, T., & Comings
Affiliations
  • Wake Forest University Health Sciences (US)
  • Weill Cornell Medicine (US)
  • City Of Hope National Medical Center (US)
  • Chang Jung Christian University (TW)
Venue
Neuropsychiatric Disease and Treatment
Published
2008-11
Volume
4
Issue
5
Pages
893
ISSN
1176-6328 (ISSN-L)
OpenAlex
W2027531652
Cited by
248
References
111
Citations by year
2026: 3 · 2025: 23 · 2024: 30 · 2023: 31 · 2022: 21 · 2021: 20 · 2020: 11 · 2019: 9 · 2018: 15 · 2017: 15 · 2016: 13 · 2015: 16 · 2014: 8 · 2013: 7 · 2012: 6
FWCI
4.68
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
  • OpenBU (Boston University) (submittedVersion)
Funders
  • U.S. Department of Health and Human Services
  • U.S. Department of Veterans Affairs
  • National Institute on Alcohol Abuse and Alcoholism (R01 AA07112, K05AA00219, R01-AA07112 and K05-AA00219, R01AA007112, K05AA000219)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
attention deficit hyperactivity disorder, reward deficiency syndrome, dopaminergic system, dopaminergic genes, genetic polymorphism, drug-seeking behavior, addiction, compulsive behavior, nutraceuticals, early diagnosis, ADHD subtypes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review